home / stock / clxpf / clxpf news

CLXPF News and Press, Canadian Lynx Pete Ltd From 03/25/21

Stock Information
Company Name: Canadian Lynx Pete Ltd
Stock Symbol: CLXPF
Market: OTC
Website: cybin.com
Menu
CLXPF CLXPF Quote CLXPF Short CLXPF News CLXPF Articles CLXPF Message Board
Get CLXPF Alerts

News, Short Squeeze, Breakout and More Instantly...
CLXPF - Cybin Inc. (NEO: CYBN) in Prime Position as Interest in Psychedelic Medicine Surges

NEW YORK, March 25, 2021 (GLOBE NEWSWIRE) -- via InvestorWire — Cybin Inc. (NEO: CYBN) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ trusted brands within the InvestorBrandNetwork (“IBN”), a mu...
CLXPF - Cybin inks drug development agreement with Catalent

Cybin (CLXPF) has signed a drug development agreement with Catalent (CTLT) to gain access to its proprietary Zydis orally disintegrating tablet ((ODT)) technology for the delivery of Cybin's novel deuterated tryptamine ((CYB003)), a potential therapy for treatment-resistant psy...

CLXPF - Cybin Signs Drug Development Agreement with Catalent for its Fast-Dissolve Formulation of Novel, Deuterated Tryptamine (CYB003)

Cybin Inc. ( NEO:CYBN ) (OTCQB:CLXPF) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has signed a drug development agreement with Catalent, Inc. (NYSE:CTLT) the ...

CLXPF - Cybin gives update on psychedelic molecules progress

Cybin  (CLXPF) announces that it is progressing its CYB003 and CYB004 proprietary psychedelic molecules into Investigational New Drug (“IND”)-enabling studies.The company said that it has also initiated an API manufacturing contract with a strategic pharmaceutical...
CLXPF - Cybin Progresses Two Psychedelic Investigational New Drug ("IND") Candidates and Announces Completion of Its 20th Pre-Clinical Study

Cybin Inc. ( NEO:CYBN ) (OTCQB:CLXPF) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has completed its 20 th pre-clinical study and is progressing its CYB003...

CLXPF - Cybin to Present at the Oppenheimer 31st Annual Healthcare Conference

Cybin Inc. ( NEO:CYBN ) (OTCQB:CLXPF) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that Doug Drysdale, Chief Executive Officer, will be presenting a business and pipel...

CLXPF - Cybin to Present at the Stifel GMP Healthcare Conference - Healthcare Psychedelics: Addressing the Global Mental Health Crisis

Cybin Inc. ( NEO:CYBN ) (OTCQB:CLXPF) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that Doug Drysdale, Chief Executive Officer, will be presenting a business and pipel...
CLXPF - With Recent Advancements, North America Is Expected To Dominate Psychedelic Drugs Market

Palm Beach, FL – March 9, 2021 – The time of “Tune In… Turn On… and Dropout” psychedelics, such as certain, mushrooms and of course, LSD were not only not legal, but no researcher could even suggest studying the compounds… they were universal...

CLXPF - Cybin Announces API Synthesis and Optimization of Multiple Tryptamine Derivatives and Nomination of Two Deuterated Candidates for Full IND Enabling Studies Based on Second Milestone Achievement Pursuant to the Adelia Acquisition

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Cybin Inc. ( NEO:CYBN ) (OTCQB:CLXPF) (“ Cybin ” or the “ Company ”), a life sciences company focused on psychedelic pharmaceutical t...

CLXPF - Cybin Inc. Shares Commence Trading on the OTCQB Venture Market on March 8, 2021

Cybin Inc. ( NEO:CYBN ) (OTCQB:CLXPF) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that its shares commence trading on the OTCQB ® Venture Market (the “...
Previous 10 Next 10